INVESTORS
Cancer immunotherapy drugs are by far the fastest-growing segment of the oncology drugs industry.
multimmune GmbH's cancer theranostics programs have been supported by investment from a number of sources:
- Technology Investment Fund Bayern III GmbH & Co. KG
- S-Refit AG / Sobera Capital GmbH)
- RAABE Verögensverwaltungs GmbH
- SilverSky LifeSciences GmbH
- Private investors